New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
09:07 EDTITMNInterMune price target raised to $22 from $17 at Canaccord
Canaccord raised Buy rated InterMune's price target to $22 to reflect increased changes of ASCEND trial success.
News For ITMN From The Last 14 Days
Check below for free stories on ITMN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
11:19 EDTITMNInterMune July weekly volatility elevated
Subscribe for More Information
July 17, 2014
12:42 EDTITMNInterMune receives FDA Breakthrough Therapy Designation for pirfenidone
InterMune announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S. FDA. This designation is reserved for drugs that are intended to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Pirfenidone is an investigational treatment for adult patients with idiopathic pulmonary fibrosis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use